We explored the transcriptomic distribution of the metabotropic glutamate receptors in the developmental phase of GBM and identified Group II metabotropic receptors as being highly expressed, with mGluR3 being an important modulatory receptor. The gene discussed is GRM3; the disease is glioblastoma.